AX-2026-042667 · IGF-1 LR3 · SWB lot SWB-2505-N7884

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	96.81	% area	≥ 95.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	3.19	% area	≤ 5.0	PASS
Largest single impurity	RP-HPLC — des-13-residue N-extension (native IGF-1)	1.67	% area	≤ 1.00	FAIL
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	86.01	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	83.27	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	0.11	mg	0.1 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	0.092	mg	0.1 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	92.0	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	7.03	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	6.42	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.54	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.72	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	16.83	min	16.92 ± 0.50 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.30	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	74,855	—	≥ 20,000	PASS
Resolution to nearest impurity	vs disulfide-scrambled isomer	2.46	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 74,855, and skew follows the reported asymmetry factor of 1.30. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.67 % impurity against a 96.81 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	IGF-1 LR3 — main peak	16.83	4,705,266	96.81	—
2	des-13-residue N-extension (native IGF-1)	14.59	81,167	1.67	-1441.712
3	disulfide-scrambled isomer	17.45	30,620	0.63	0.000
4	truncated (1-70)	14.89	24,302	0.50	-1385.688
5	oxidised Met59 (+16 Da)	16.11	10,693	0.22	+15.995
6	aggregated dimer	20.03	8,263	0.17	+9105.241
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	7.03
Counter-ion (acetate)	ion chromatography	6.42
Residual solvent + inorganic residue	estimated	0.54
Total peptide content	by difference	86.01
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	97.30	96.81	divergence +0.07 pp vs batch median
Total impurities (% area)	2.70	3.19
Largest single impurity (% area)	not stated	1.67
Water (%)	6.1	7.03
Counter-ion (%)	not stated	6.42
Peptide content (%w/w)	not stated	86.01
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 24 d) → laboratory (courier, dry ice, 2 d) → assay.
Assay date: 09 Dec 2025
Submitted to the index: 03 Jan 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That the protein is correctly folded. Reverse-phase chromatography measures hydrophobic heterogeneity. A correctly-massed, chromatographically-homogeneous recombinant protein can be entirely mis-paired at its disulfides. Purity here is an upper bound and nothing more.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 1

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

survivor_lots03 Jan 2026

Even a perfectly blind purchase is a lot somebody chose to test. Provenance fixes one selection problem and leaves the other standing.

Section 7

Related records

Same batch — lot SWB-2505-N7884 n=12

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-020072	SWB-2505-N7884	Medutest	2025-Q4	97.36	6.58	86.0	Laboratory-retained	1	MARGINAL
AX-2025-020073	SWB-2505-N7884	Kestrel	2025-Q4	98.63	6.08	94.0	Buyer-sourced	0	PASS
AX-2025-020074	SWB-2505-N7884	VendorInvestigate	2025-Q4	97.12	6.52	103.0	Buyer-sourced	0	PASS
AX-2025-020075	SWB-2505-N7884	Janoshik	2025-Q4	97.58	6.05	—	Buyer-sourced	0	PASS
AX-2025-020076	SWB-2505-N7884	Janoshik	2025-Q4	97.08	6.47	101.0	Buyer-sourced	0	PASS
AX-2025-020077	SWB-2505-N7884	Janoshik	2025-Q4	97.22	5.99	—	Buyer-sourced	0	PASS
AX-2025-020078	SWB-2505-N7884	Janoshik	2025-Q4	97.02	6.31	93.0	Buyer-sourced	0	PASS
AX-2025-020079	SWB-2505-N7884	PeptideMeter	2025-Q4	97.23	7.01	100.0	Buyer-sourced	0	PASS
AX-2025-020080	SWB-2505-N7884	Janoshik	2025-Q4	97.18	6.59	93.0	Buyer-sourced	0	PASS
AX-2025-020081	SWB-2505-N7884	Janoshik	2025-Q4	97.25	6.48	94.0	Buyer-sourced	0	PASS
AX-2025-020082	SWB-2505-N7884	Medutest	2025-Q4	97.58	6.64	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent IGF-1 LR3 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042503	Homopeptide	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	0	PASS
AX-2026-042509	Homopeptide	HOMO-2607-P5131	Medutest	2026-Q3	98.63	6.23	103.0	Buyer-sourced	0	PASS
AX-2026-041930	SinoPep	SNP-2606-D4620	Medutest	2026-Q3	98.54	5.37	93.8	Buyer-sourced	0	PASS
AX-2026-041931	SinoPep	SNP-2606-D4620	PeptideMeter	2026-Q3	97.93	5.19	93.4	Buyer-sourced	0	PASS
AX-2026-041924	SinoPep	SNP-2606-D4620	Janoshik	2026-Q3	97.95	5.34	—	Buyer-sourced	0	PASS
AX-2026-042504	Homopeptide	HOMO-2607-P5131	Janoshik	2026-Q3	99.08	6.26	105.0	Buyer-sourced	0	PASS
AX-2026-042499	Homopeptide	HOMO-2607-P5131	Medutest	2026-Q3	98.48	5.98	88.0	Buyer-sourced	1	MARGINAL
AX-2026-042508	Homopeptide	HOMO-2607-P5131	Janoshik	2026-Q3	98.89	6.22	—	Buyer-sourced	1	MARGINAL

Other recent SWB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042637	Semaglutide	SWB-2602-X7905	Janoshik	2026-Q3	98.37	4.26	102.9	Buyer-sourced	PASS
AX-2026-042645	Semaglutide	SWB-2602-X7905	Medutest	2026-Q3	98.48	4.52	95.2	Buyer-sourced	PASS
AX-2026-042642	Semaglutide	SWB-2602-X7905	PeptideMeter	2026-Q3	97.96	4.48	90.8	Buyer-sourced	PASS
AX-2026-042640	Semaglutide	SWB-2602-X7905	PeptideMeter	2026-Q3	98.55	4.29	—	Buyer-sourced	PASS
AX-2026-042638	Semaglutide	SWB-2602-X7905	Janoshik	2026-Q3	98.74	3.65	—	Buyer-sourced	PASS
AX-2026-042639	Semaglutide	SWB-2602-X7905	Janoshik	2026-Q3	98.77	4.21	—	Supplier-supplied	PASS
AX-2026-042641	Semaglutide	SWB-2602-X7905	Janoshik	2026-Q3	98.86	4.48	99.1	Buyer-sourced	PASS
AX-2026-042644	Semaglutide	SWB-2602-X7905	PeptideMeter	2026-Q3	98.76	3.57	97.7	Buyer-sourced	PASS